Discover key insights from Neurocrine Biosciences' Q2 2025 earnings, featuring record INGREZZA growth, CRENESSITY's rapid adoption, and strategic ...

Neurocrine (NBIX) delivered earnings and revenue surprises of +8.16% and +5.72%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2025, and updated its 2025 financial guidance.

Analysts estimate that United Therapeutics will report an earnings per share (EPS) of $6.87. The announcement from United Therapeutics is eagerly anticipated, with investors seeking news of surpassing ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the best strong buy healthcare stocks to buy now. On July 22, Morgan ...

Atai Life Sciences and its partner Recognify Life Sciences said on Friday their experimental drug did not meet the main goal in a mid-stage trial for patients with schizophrenia-linked cognitive ...

Detailed price information for Neurocrine Bioscienc (NBIX-Q) from The Globe and Mail including charting and trades.

Fintel reports that on July 21, 2025, Truist Securities initiated coverage of Neurocrine Biosciences (NasdaqGS:NBIX) with a ...

SAN FRANCISCO -- Crinecerfont (Crenessity) may help improve metabolic profiles of adults and children with classic congenital adrenal hyperplasia (CAH), analyses of phase III CAHtalyst trial data ...

Detailed price information for Neurocrine Bioscienc (NBIX-Q) from The Globe and Mail including charting and trades.

PicnicHealth, a health technology company dedicated to advancing the next generation of non-interventional research, today announced its research collaboration with Neurocrine Biosciences, Inc.

One-year data from CAHtalyst™ Adult study demonstrated lasting reductions in glucocorticoid dose and improvement in clinical outcomes in adults with ...